Trial · NCT04501874
A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
NCT04501874, Phase 2, Completed, Embera NeuroTherapeutics, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder. Trials, record NCT04501874. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04501874
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
- NCT number
- NCT04501874
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 82 participants, actual
- Lead sponsor
- Embera NeuroTherapeutics, Inc.
- Conditions
- Cocaine Use Disorder
- Interventions
- EMB-001, EMB-001 Placebo
- First posted
- 2020-08-06
- Last updated
- 2026-09-21
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Continuous Abstinence From Cocaine Use | Week 11 to Week 13 | The Primary Endpoint is the Percentage of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment using the Timeline Follow Back; days of abstinence, confirmed by Urine benzoylecgonine (BE) |
| Secondary | Change in Cocaine-use Days (Weekly Average) | Final 3 weeks of treatment (Weeks 11, 12 and 13 for subjects who complete the trial fully, but whichever weeks are the final 3 weeks for subjects who do not fully complete the trial) compared to the 28 days prior to screening. | Weekly cocaine use days 28 days prior to Screening (Time Line Follow-back (TLFB) only) to weekly use days during final 3 weeks of treatment (TLFB confirmed by urine BE) |
| Secondary | Reduction in Total Cocaine Craving Questionnaire-Brief Score | Baseline to Week 13 (Day 91) | The Cocaine Craving Questionnaire-Brief (CCQ-B) assesses current cocaine craving in routine clinical practice. The CCQ-B is a 10 item questionnaire and items are scored on a one to seven scale. Total responses are then divided by 10 to achieve a total craving score between 1.0 (least craving) to 7.0 (most craving). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22236504 | BACKGROUND |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01DA038879 | EMB-001: A novel combination therapy for the treatment of cocaine-use disorder | MCCARTHY, BRUCE | EMBERA NEUROTHERAPEUTICS, INC. | NATIONAL INSTITUTE ON DRUG ABUSE | 2016 to 2019 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04501874
GET https://conductscience.org/api/trials/v1/NCT04501874/registered